ImmunoCellular Therapeutics to Present at the Annual Meeting of the Congress of Neurological Surgeons

Company Chairman's Poster to Highlight ICT-107 Data

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based therapies, today announced that John Yu, MD, Chairman, will deliver an oral presentation at the Annual Meeting of the Congress of Neurological Surgeons. The abstract titled, “A Multi-Epitope Pulsed Dendritic Cell Vaccine (ICT-107) Targeting Glioblastoma Cancer Stem Cells Reduces the Cancer Stem Cell Population in Recurrent Tumor and Is Associated with Increased Progression-free Survival,” will be presented at 2:54 p.m. today in room 151B at the Washington Convention Center in Washington, D.C.

The presentation outlines immune response data and correlations of increased progression-free survival (PFS) and overall survival (OS) from the previously completed Phase I clinical trial of ICT-107. Of the 16 patients in the study, 6 showed no signs of tumor recurrence, with 3 experiencing no disease progression almost 4 years after vaccination, while the other three have exhibited PFS for at least 2.5 years. The expression of four ICT-107 antigens in the pre-vaccine tumors correlates with prolonged PFS and OS in newly diagnosed GBM patients. The decrease in tumor activity and positive antitumor cytokine responses observed in participants vs. unvaccinated patients suggest that recurrent tumors bear more chemoresistant and radioresistant cancer stem cells; and ICT-107 vaccinated patients have a decreased proportion of cancer stem cells from immunological targeting.

The poster that will accompany the oral presentation can be viewed at: http://w3.cns.org/dp/2011CNS/987.pdf

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell-based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



CONTACT:

ImmunoCellular Therapeutics, Ltd.
CEOcast, Inc.
James Young, 212-732-4300
Investor Relations
[email protected]

KEYWORDS:   United States  North America  California  District of Columbia

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Clinical Trials  Infectious Diseases  Oncology

MEDIA:

Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.